Generic placeholder image

Recent Patents on Cardiovascular Drug Discovery

Editor-in-Chief

ISSN (Print): 2212-3962
ISSN (Online): 1574-8901

Current Status and Ongoing Development of Reversing Agents for Novel Oral Anticoagulants (NOACs)

Author(s): Davide Capodanno, Giuseppe Giacchi and Corrado Tamburino

Volume 8, Issue 1, 2013

Page: [2 - 9] Pages: 8

DOI: 10.2174/15748901112079990013

Price: $65

Abstract

Novel oral anticoagulants (NOACs) have been associated with multiple safety benefits compared with vitamin K antagonists in patients with diseases at high thromboembolic potential, including nonvalvular atrial fibrillation. Although these agents have several distinct advantages, they are limited by the lack of a proven antidote, which may represent a major concern in case of life-threatening bleeding. Several different drugs and compounds are currently under investigation as reversing agents of NOACs. This article provides an overview of potential NOACs antidotes, including recent patents of emerging compounds.

Keywords: Antidote, direct inhibitor Factor IIa, direct inhibitor Factor Xa, novel oral anticoagulants, reversing agent.

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy